Concordia Healthcare Corp. announces Exclusive Distribution Agreement for Ulesfia® with Lachlan Pharma Holdings

January 6, 2014


TORONTO, Jan. 6, 2014 /PRNewswire/ – Concordia Healthcare Corp. (“Concordia“), an integrated, specialty healthcare company focused on the
acquisition of legacy pharmaceutical products, the acquisition and
development of orphan drugs, and distribution of medical devices
servicing the diabetic population announced today that it has entered
into an Exclusive Distribution Agreement with Lachlan Pharma Holdings
(“Lachlan“), a global pharmaceutical company, with a term of five years for the
exclusive distribution of Ulesfia® (benzyl alcohol) Lotion in the
United States. Lachlan has an agreement with Zylera Pharmaceuticals,
LLC (“Zylera“) to commercialize Ulesfia® Lotion in the United States.

“The Exclusive Distribution Agreement for Ulesfia® Lotion with Lachlan
provides Concordia access to Zylera’s seasoned sales force as well as
their wholesale and retail network,” said Mark Thompson, chief
executive officer of Concordia. “We believe that Zylera is an
excellent partner which will help grow the existing sales of Ulesfia®
Lotion across the United States.” Ulesfia® Lotion is a prescription
non-pesticide Head Lice Treatment currently sold in the United States.

About Concordia

Concordia is a diverse healthcare company focused on legacy
pharmaceutical products, orphan drugs and medical devices for the
diabetic population.

The company’s legacy pharmaceutical business consists of an
ADHD-treatment drug, Kapvay® (clonidine extended release tablets),
Ulesfia® (benzyl alcohol) Lotion a Head Lice Treatment, and an
Asthma-related medication, Orapred ODT® (prednisolone sodium phosphate
orally disintegrating tablets). Concordia’s Specialty Healthcare
Distribution (SHD) division (Complete Medical Homecare) distributes
medical supplies targeting diabetes and related conditions. Concordia’s
orphan drug division, Pinnacle Biologics Inc., markets Photofrin® in the United States.

Concordia operates out of facilities in Oakville, Ontario, Lenexa,
Kansas (near Kansas City, Missouri), Chicago, Illinois and Bridgetown,

Notice regarding forward-looking statements:

This release includes forward-looking statements regarding Concordia and
its business. Often, but not always, forward-looking statements can be
identified by the use of words such as “plans”, “is expected”,
“expects”, “scheduled”, “intends”, “contemplates”, “anticipates”,
“believes”, “proposes” or variations (including negative variations) of
such words and phrases, or state that certain actions, events or
results “may”, “could”, “would”, “might” or “will” be taken, occur or
be achieved. Such statements are based on the current expectations of
Concordia’s management. The forward-looking events and circumstances
discussed in this release may not occur by certain specified dates or
at all and could differ materially as a result of known and unknown
risk factors and uncertainties affecting the company, including risks
regarding the pharmaceutical industry, the ability to expand the
existing sales of Concordia’s products, including Ulesfia® Lotion, in
the United States and other geographic regions, as applicable, the
receipt of approval to market Concordia’s products in certain markets,
the ability to locate partners to promote and grow the existing sales
of Concordia’s products, including Ulesfia® Lotion, the further
development of Concordia’s products, the growth of Concordia, failure
to obtain regulatory approvals, economic factors, the equity markets
generally and many other factors beyond the control of Concordia.
Although Concordia has attempted to identify important factors that
could cause actual actions, events or results to differ materially from
those described in forward-looking statements, there may be other
factors that cause actions, events or results to differ from those
anticipated, estimated or intended. No forward-looking statement can be
guaranteed. Except as required by applicable securities laws,
forward-looking statements speak only as of the date on which they are
made and Concordia undertakes no obligation to publicly update or
revise any forward-looking statement, whether as a result of new
information, future events, or otherwise.

SOURCE Concordia Healthcare Corp.

Source: PR Newswire

comments powered by Disqus